ClinicalTrials.gg
CompletedNCT00662038PIPF-012Updated Mar 29, 2017Results posted

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 3 interventional study of pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years to 84 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,058
Allocation
Not applicable
Ages
40 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
2nd of 21
1,058 · median 89
Started
2008
the only one that year
Phase 3
6 of 21
1 open now
Registered
4th of 21
by date
Lead sponsor
5 of 21
Genentech, Inc.

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 6 in phase 3, and was the 4th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.

Read the detailed description

This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. Eligible patients must complete the final visit for their qualifying study, have not permanently discontinued study drug in their qualifying study, and meet all of the eligibility criteria noted in this protocol.

Since data from the qualifying study may remain blinded during patient enrollment in PIPF-012, all patients will be treated as if they were taking placebo in their qualifying study. At the start of PIPF-012 participation, each patient will escalate the dose of pirfenidone.

The duration of treatment for each patient will vary and will continue until pirfenidone is commercially or otherwise available in his/her geographic region or the study is terminated by the sponsor for reasons outlined in the protocol.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • idiopathic
  • pulmonary
  • fibrosis
04

Who can participate

Ages eligible
40 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completes the qualifying clinical study final visit
  • In the opinion of the principal investigator (PI), has been generally compliant with study requirements during the qualifying study, or must be considered eligible to enroll in PIPF-012 by the InterMune medical monitor
  • Is able to provide and comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Is pregnant or lactating
  • Has known to any of the components of the study drug
  • Starts participation in another interventional clinical trial between the end of participation in the qualifying InterMune clinical trial and entry into PIPF-012
  • Receives concomitant and/or excluded medications as defined in the protocol
  • Permanently discontinues study drug during the qualifying study for any reason before study completion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,058 participants (actual)

Study arms

  • Experimental
    Treatment

    pirfenidone

    Drug: pirfenidone

Interventions

  • Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    An adverse event defined as any unfavorable, harmful, or pathologic change in a research participant administered a pharmaceutical study treatment as indicated by physical signs, symptoms, and/or clinically significant laboratory abnormalities that occurred during the treatment and the post-treatment period, regardless of suspected cause.

    Time frame: 7.5 years

07

Results

Posted Mar 29, 2017

Participant flow

Participant flow — Overall Study
MilestonePirfenidone
Started1058
Completed427
Not completed631
Withdrew: Reason not specified3
Withdrew: Withdrawn consent22
Withdrew: Withdrawal by subject83
Withdrew: Sponsor decision1
Withdrew: Physician decision19
Withdrew: Lung transplantation44
Withdrew: Lost to follow-up1
Withdrew: Death95
Withdrew: Adverse event358
Withdrew: Continued treatment5

Outcome measures

PrimaryPercentage of Participants With Adverse Events

An adverse event defined as any unfavorable, harmful, or pathologic change in a research participant administered a pharmaceutical study treatment as indicated by physical signs, symptoms, and/or clinically significant laboratory abnormalities that occurred during the treatment and the post-treatment period, regardless of suspected cause.

Time frame:
7.5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsPirfenidone
Percentage of Participants With Adverse Events98.0

Adverse events

Collected over 7.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pirfenidone—571/1,058 (54%)1,027/1,058 (97.1%)
Most frequent serious events
Showing 10 of 370
Most frequent serious events
EventPirfenidone
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders230/1058
PneumoniaInfections and infestations90/1058
BronchitisInfections and infestations32/1058
Acute respiratory failureRespiratory, thoracic and mediastinal disorders30/1058
Respiratory failureRespiratory, thoracic and mediastinal disorders29/1058
Atrial fibrillationCardiac disorders26/1058
Coronary artery diseaseCardiac disorders20/1058
SyncopeNervous system disorders20/1058
Pulmonary embolismRespiratory, thoracic and mediastinal disorders19/1058
HypoxiaRespiratory, thoracic and mediastinal disorders17/1058
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPirfenidone
CoughRespiratory, thoracic and mediastinal disorders330/1058
DyspnoeaRespiratory, thoracic and mediastinal disorders325/1058
NauseaGastrointestinal disorders305/1058
Upper respiratory tract infectionInfections and infestations295/1058
BronchitisInfections and infestations254/1058
DiarrhoeaGastrointestinal disorders242/1058
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders221/1058
FatigueGeneral disorders210/1058
NasopharyngitisInfections and infestations202/1058
DizzinessNervous system disorders176/1058

Baseline characteristics

All treated participants

Age, Continuous
Age, Continuous(years)Pirfenidone
Mean68.5 ± 7.47
Sex: Female, Male
Sex: Female, Male(Participants)Pirfenidone
Female268
Male790
08

Study locations

1 site
  • Genentech, Inc.
    South San Francisco, California 94080-4990, United States
09

References and documents

Publications

  • Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. No abstract available. PubMed 30950636 ↗
  • Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13. PubMed 28898890 ↗
  • Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016. PubMed 26835133 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2008
First posted
Apr 21, 2008
Start
Aug 2008
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Results first posted
Mar 29, 2017
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00662038
Lead sponsor
Genentech, Inc.
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 21, 2008
Start date
Aug 2008
Primary completion
Feb 2016
Completion
Feb 2016
Results posted
Mar 29, 2017
Last update
Mar 29, 2017

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion